CoChat
Sign Up
Cited by 120

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Clonal evolution in leukemia

Ferrando, Adolfo A, López-Otín, Carlos·2017·Nature Medicine
DOI 10.1038/nm.4410
Open this paper in CoChat — free account

Abstract

Human leukemias are liquid malignancies characterized by diffuse infiltration of the bone marrow by transformed hematopoietic progenitors. The accessibility of tumor cells obtained from peripheral blood or through bone marrow aspirates, together with recent advances in cancer genomics and single-cell molecular analysis, have facilitated the study of clonal populations and their genetic and epigenetic evolution over time with unprecedented detail. The results of these analyses challenge the classic view of leukemia as a clonal homogeneous diffuse tumor and introduce a more complex and dynamic scenario. In this review, we present current concepts on the role of clonal evolution in lymphoid and myeloid leukemia as a driver of tumor initiation, disease progression and relapse. We also discuss the implications of these concepts in our understanding of the evolutionary mechanisms involved in leukemia transformation and therapy resistance.

Overview

Integrity signals

Registry

Crossref · 10.1038/nm.4410

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 126

  1. Merlo, L.M., Pepper, J.W., Reid, B.J. & Maley, C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924–935 (2006). · DOI
  2. Greaves, M. Evolutionary determinants of cancer. Cancer Discov. 5, 806–820 (2015). · DOI
  3. Puente, X.S. & López-Otín, C. The evolutionary biography of chronic lymphocytic leukemia. Nat. Genet. 45, 229–231 (2013). · DOI
  4. Landau, D.A., Carter, S.L., Getz, G. & Wu, C.J. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28, 34–43 (2014). · DOI
  5. Greaves, M. Leukaemia 'firsts' in cancer research and treatment. Nat. Rev. Cancer 16, 163–172 (2016). · DOI
  6. Dick, J.E. Stem cell concepts renew cancer research. Blood 112, 4793–4807 (2008). · DOI
  7. Jan, M. & Majeti, R. Clonal evolution of acute leukemia genomes. Oncogene 32, 135–140 (2013). · DOI
  8. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990). · DOI · Paper page
  9. Song, W.J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166–175 (1999). · DOI · Paper page
  10. Smith, M.L., Cavenagh, J.D., Lister, T.A. & Fitzgibbon, J. Mutation of CEBPA in familial acute myeloid leukemia. N. Engl. J. Med. 351, 2403–2407 (2004). · DOI
  11. Hahn, C.N. et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 43, 1012–1017 (2011). · DOI
  12. Noris, P. et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood 122, 1987–1989 (2013). · DOI
  13. Polprasert, C. et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27, 658–670 (2015). · DOI
  14. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226–1231 (2013). · DOI
  15. Zhang, M.Y. et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat. Genet. 47, 180–185 (2015). · DOI
  16. Moriyama, T. et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 16, 1659–1666 (2015). · DOI
  17. Greaves, M.F., Maia, A.T., Wiemels, J.L. & Ford, A.M. Leukemia in twins: lessons in natural history. Blood 102, 2321–2333 (2003). · DOI
  18. Sanjuan-Pla, A. et al. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood 126, 2676–2685 (2015). · DOI
  19. Hong, D. et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319, 336–339 (2008). · DOI
  20. Greaves, M. Infection, immune responses and the aetiology of childhood leukaemia. Nat. Rev. Cancer 6, 193–203 (2006). · DOI
  21. Jacobs, K.B. et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat. Genet. 44, 651–658 (2012). · DOI · Paper page
  22. Laurie, C.C. et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat. Genet. 44, 642–650 (2012). · DOI · Paper page
  23. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012). · DOI · Paper page
  24. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011). · DOI
  25. Li, A.H., Rosenquist, R., Forestier, E., Lindh, J. & Roos, G. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implications for minimal residual disease detection. Leuk. Res. 25, 1033–1045 (2001). · DOI
  26. de Haas, V. et al. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia 15, 134–140 (2001). · DOI
  27. Notta, F. et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469, 362–367 (2011). · DOI
  28. Paguirigan, A.L. et al. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci. Transl. Med. 7, 281re2 (2015). · DOI · Paper page
  29. Puente, X.S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519–524 (2015). · DOI
  30. Landau, D.A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525–530 (2015). · DOI
  31. Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204–212 (2017). · DOI
  32. Mossner, M. et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 128, 1246–1259 (2016). · DOI
  33. Miyamoto, T., Weissman, I.L. & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl. Acad. Sci. USA 97, 7521–7526 (2000). · DOI · Paper page
  34. Damm, F. et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 4, 1088–1101 (2014). · DOI
  35. Kikushige, Y. et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246–259 (2011). · DOI
  36. Chung, S.S. et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci. Transl. Med. 6, 238ra71 (2014). · DOI
  37. Sperling, A.S., Gibson, C.J. & Ebert, B.L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5–19 (2017). · DOI
  38. Walter, M.J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090–1098 (2012). · DOI
  39. Green, M.R. et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. USA 112, E1116–E1125 (2015). · DOI
  40. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014). · DOI · Paper page
  41. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. USA 111, 2548–2553 (2014). · DOI · Paper page
  42. Horiike, S. et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 13, 1235–1242 (1999). · DOI
  43. Side, L.E. et al. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosom. Cancer 39, 217–223 (2004). · DOI
  44. Gibson, C.J. et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J. Clin. Oncol. 35, 1598–1605 (2017). · DOI · Paper page
  45. Young, N.S., Calado, R.T. & Scheinberg, P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108, 2509–2519 (2006). · DOI · Paper page
  46. Socié, G., Rosenfeld, S., Frickhofen, N., Gluckman, E. & Tichelli, A. Late clonal diseases of treated aplastic anemia. Semin. Hematol. 37, 91–101 (2000). · DOI
  47. Maciejewski, J.P., Risitano, A., Sloand, E.M., Nunez, O. & Young, N.S. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99, 3129–3135 (2002). · DOI
  48. Dumitriu, B. et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood 125, 706–709 (2015). · DOI
  49. Katagiri, T. et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 118, 6601–6609 (2011). · DOI
  50. Afable, M.G. II et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 117, 6876–6884 (2011). · DOI
  51. Hillmen, P., Lewis, S.M., Bessler, M., Luzzatto, L. & Dacie, J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333, 1253–1258 (1995). · DOI
  52. Ogawa, S. Clonal hematopoiesis in acquired aplastic anemia. Blood 128, 337–347 (2016). · DOI
  53. Quentin, S. et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 117, e161–e170 (2011). · DOI
  54. Horwitz, M., Benson, K.F., Person, R.E., Aprikyan, A.G. & Dale, D.C. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat. Genet. 23, 433–436 (1999). · DOI
  55. Klein, C. et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat. Genet. 39, 86–92 (2007). · DOI
  56. Devriendt, K. et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat. Genet. 27, 313–317 (2001). · DOI
  57. Bonilla, M.A. et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N. Engl. J. Med. 320, 1574–1580 (1989). · DOI
  58. Rosenberg, P.S. et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br. J. Haematol. 150, 196–199 (2010). · DOI
  59. Germeshausen, M., Ballmaier, M. & Welte, K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 109, 93–99 (2007). · DOI
  60. Skokowa, J. et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood 123, 2229–2237 (2014). · DOI
  61. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627, quiz 3699 (2013). · DOI · Paper page
  62. Ortmann, C.A. et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372, 601–612 (2015). · DOI · Paper page
  63. Cortés, J.R. & Palomero, T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr. Opin. Hematol. 23, 434–443 (2016). · DOI
  64. Shaknovich, R., De, S. & Michor, F. Epigenetic diversity in hematopoietic neoplasms. Biochim. Biophys. Acta 1846, 477–484 (2014).
  65. Guièze, R. & Wu, C.J. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood 126, 445–453 (2015). · DOI
  66. Li, S., Mason, C.E. & Melnick, A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr. Opin. Genet. Dev. 36, 100–106 (2016). · DOI
  67. Kulis, M. et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 44, 1236–1242 (2012). · DOI
  68. Figueroa, M.E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010). · DOI
  69. Milani, L. et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115, 1214–1225 (2010). · DOI
  70. Geng, H. et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2, 1004–1023 (2012). · DOI
  71. Li, S. et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat. Med. 22, 792–799 (2016). · DOI
  72. Pan, H. et al. Epigenomic evolution in diffuse large B-cell lymphomas. Nat. Commun. 6, 6921 (2015). · DOI
  73. Sandoval, J. et al. Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 160, 406–409 (2013). · DOI
  74. Landau, D.A. et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26, 813–825 (2014). · DOI
  75. Oakes, C.C. et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat. Genet. 48, 253–264 (2016). · DOI
  76. Heller, G. et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia 30, 1861–1868 (2016). · DOI
  77. Feinberg, A.P., Koldobskiy, M.A. & Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284–299 (2016). · DOI · Paper page
  78. Greenblatt, S.M. & Nimer, S.D. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 28, 1396–1406 (2014). · DOI
  79. Roberts, K.G. & Mullighan, C.G. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat. Rev. Clin. Oncol. 12, 344–357 (2015). · DOI
  80. Woods, B.A. & Levine, R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Immunol. Rev. 263, 22–35 (2015). · DOI
  81. Shen, H. & Laird, P.W. Interplay between the cancer genome and epigenome. Cell 153, 38–55 (2013). · DOI
  82. Oakes, C.C. et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 4, 348–361 (2014). · DOI
  83. Amabile, G. et al. Dissecting the role of aberrant DNA methylation in human leukaemia. Nat. Commun. 6, 7091 (2015). · DOI
  84. Zhang, X. et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat. Genet. 48, 1014–1023 (2016). · DOI · Paper page
  85. Pasqualucci, L. et al. Expression of the AID protein in normal and neoplastic B cells. Blood 104, 3318–3325 (2004). · DOI
  86. Gorre, M.E. & Sawyers, C.L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr. Opin. Hematol. 9, 303–307 (2002). · DOI
  87. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002). · DOI
  88. Branford, S., Melo, J.V. & Hughes, T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114, 5426–5435 (2009). · DOI
  89. Cortes, J. et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110, 4005–4011 (2007). · DOI
  90. Liu, T.M. et al. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood 126, 61–68 (2015). · DOI · Paper page
  91. Burger, J.A. et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat. Commun. 7, 11589 (2016). · DOI · Paper page
  92. Ahn, I.E. et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129, 1469–1479 (2017). · DOI · Paper page
  93. Smith, C.C. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485, 260–263 (2012). · DOI
  94. Goto, E. et al. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood 118, 1600–1609 (2011). · DOI
  95. Maus, M.V., Grupp, S.A., Porter, D.L. & June, C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625–2635 (2014). · DOI
  96. Davila, M.L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014). · DOI
  97. Restifo, N.P., Smyth, M.J. & Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16, 121–126 (2016). · DOI
  98. Chung, E.Y. et al. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J. Clin. Invest. 122, 2257–2266 (2012). · DOI
  99. Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015). · DOI
  100. Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016). · DOI
  101. Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406–2410 (2016). · DOI
  102. Rayes, A., McMasters, R.L. & O'Brien, M.M. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer 63, 1113–1115 (2016). · DOI
  103. Armstrong, S.A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30, 41–47 (2002). · DOI
  104. Evans, A.G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205–209 (2015). · DOI
  105. Mullighan, C.G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380 (2008). · DOI
  106. Bardini, M. et al. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia 29, 38–50 (2015). · DOI
  107. Oshima, K. et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 113, 11306–11311 (2016). · DOI
  108. Mullighan, C.G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235–239 (2011). · DOI
  109. Ma, X. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat. Commun. 6, 6604 (2015). · DOI
  110. Meyer, J.A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290–294 (2013). · DOI
  111. Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 368–371 (2013). · DOI
  112. Li, B. et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat. Med. 21, 563–571 (2015). · DOI
  113. Ariës, I.M. et al. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica 100, e132–e136 (2015). · DOI
  114. Jones, C.L. et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood 126, 2202–2212 (2015). · DOI
  115. Estey, E., Keating, M.J., Pierce, S. & Stass, S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 9, 972–976 (1995).
  116. Raghavan, M. et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 112, 814–821 (2008). · DOI
  117. Parkin, B. et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121, 369–377 (2013). · DOI
  118. Sood, R. et al. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia 30, 501–504 (2016). · DOI
  119. Krönke, J. et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 122, 100–108 (2013). · DOI
  120. Nadeu, F. et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127, 2122–2130 (2016). · DOI
  121. Pui, C.H. et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 16, 465–474 (2015). · DOI
  122. Kim, J.Y. & Gatenby, R.A. Quantitative clinical imaging methods for monitoring intratumoral evolution. Methods Mol. Biol. 1513, 61–81 (2017). · DOI
  123. Batlevi, C.L., Matsuki, E., Brentjens, R.J. & Younes, A. Novel immunotherapies in lymphoid malignancies. Nat. Rev. Clin. Oncol. 13, 25–40 (2016). · DOI
  124. Sun, J. et al. Clonal dynamics of native haematopoiesis. Nature 514, 322–327 (2014). · DOI · Paper page
  125. Kwok, B. et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 126, 2355–2361 (2015). · DOI
  126. Jones, P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484–492 (2012). · DOI · Paper page

Cited by

See all 120

Metadata

Authors
Ferrando, A. A., & López-Otín, C.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2017-10
Volume
23
Issue
10
Pages
1135-1145
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/nm.4410
Cited by
120
References
17
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review